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Multifarious immunotherapeutic approaches to cure HIV-1 infection
Nesrina Imami* and Anna A Herasimtschuk
Department of Medicine; Imperial College London; London, UK
Immunotherapy in the context oftreated HIV-1 infection aims to
improve immune responses to achieve
better control of the virus. To date, mul-
tifaceted immunotherapeutic approaches
have been shown to reduce immune acti-
vation and increase CD4 T-lymphocyte
counts, further to the effects of antiretro-
viral therapy alone, in addition to
improving HIV-1-specific T-cell
responses. While sterilizing cure of HIV-
1 would involve elimination of all repli-
cation-competent virus, a functional cure
in which the host has long-lasting control
of viral replication may be more feasible.
In this commentary, we discuss novel
strategies aimed at targeting the latent
viral reservoir with cure of HIV-1 infec-
tion being the ultimate goal, an achieve-
ment that would have considerable
impact on worldwide HIV-1 infection.
Introduction
Combination antiretroviral therapy
(cART) reduces morbidity and mortality
in HIV-1-infected individuals;1 however,
it cannot eradicate the virus and does not
enable the immune system to control
HIV-1 replication.2,3 Viral reservoirs per-
sist and viral rebound is seen following
treatment interruption.4-7 Immunother-
apy in treated HIV-1 infection aims to
diminish viral reservoirs by reversing
T-cell dysfunction and modifying
immune responses to mirror those found
in long-term nonprogressors or HIV con-
trollers.8,9 Ideally, immunotherapeutic
approaches targeting the vulnerable T-cell
population would induce and maintain
HIV-1-specific responses, increase poly-
functionality, enhance thymic function,
reduce levels of immune activation and
reverse T-cell anergy and exhaustion.
Novel approaches may further benefit
clinical outcomes by providing more sus-
tained viral control, preventing reservoir
re-seeding, reducing risk of both
HIV-1-related and inflammation-related
morbidity and mortality,10 and most opti-
mistically even eradicating the reservoir.7
In this context, the rational design of
interventions must take into consideration
the sequence, timing, dosage and kinetics
of immunotherapeutic agents, in order to
optimize the desired immune response. A
major target in HIV-1 eradication is to
reactivate latent integrated provirus in
cART-treated patients,7 however reports
suggest that current latency reversal agents
alone are not sufficient to expunge the
HIV-1 reservoir.8 The induction of robust
virus-specific cell-mediated responses that
will eliminate reactivated provirus is
thought to be key.11 The same immuno-
logical principles may apply in the absence
of eradication where functional cure is
achieved by maintenance of viral control,9
hence the renewed interest in therapeutic
vaccines and immunotherapies to be used
in conjunction with candidate latency
reversal agents.
Early Initiation of cART Facilitates
Efﬁcacious Immunotherapeutic
Intervention
Studies seeking to optimize the tim-
ing and duration of cART have
highlighted the advantages of early
intervention with antiretroviral drugs.
Initiation of cART in early HIV-1
infection results in lower residual viral
reservoirs compared to levels observed
in individuals treated during chronic
HIV-1 infection.2 Moreover, early treat-
ment with cART restrains the level of
immune activation and facilitates
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improved polyfunctionality of HIV-1-
specific T-cell responses.12 Early treat-
ment also prevents the latent viral reser-
voir from becoming dominated by
HIV-1 variants that have mutated to
escape cytotoxic T lymphocytes (CTL);
this has implications for both therapeu-
tic vaccine design and HIV cure strate-
gies.13 Furthermore, earlier initiation of
cART and higher nadir CD4 T-cell
counts have been associated with the
preservation of functional recall T-cell
responses.14 In a study investigating
interleukin (IL)-2 administration and
immunization with the therapeutic
HIV-1 vaccine RemuneTM, functional
responses were not boosted in cART-
treated HIV-1-infected patients who
had low pre-cART CD4 T-cell
counts.15 This lack of immune recovery
was postulated to be due to protracted
immunosuppression and/or clonal dys-
function,15 and differed from previous
RemuneTM studies which demonstrated
proliferative responses in patients that
had both higher nadir and pre-immu-
notherapy baseline CD4 T-cell
counts.16 For this reason, patients
enrolled in our recent Phase I immuno-
therapy trial (ClinicalTrials.gov Identi-
fier: NCT01130376) were carefully
considered in terms of CD4 T-cell
counts and duration of suppressed vir-
aemia (Fig. 1).17 On an individual
patient basis, those demonstrating the
greatest benefit from immunotherapy
(with improved clinical and immuno-
logical parameters) received cART at
earlier stages following infection, which
concurs with a number of reports.18,19
There is an emerging consensus that
early initiation of cART is an essential
aspect of long-term control of HIV-1
and likely to be critical in future latency
reversal approaches.19
Essential Role of Therapeutic
Vaccines to Provide Antigenic
Stimulus
To date no therapeutic vaccine has
been licensed for use in the treatment of
HIV-1 infection. However, immunization
in conjunction with cART may lead to a
reversal of anergy by selective induction
and activation of specific memory T-cell
responses against a number of viral pro-
teins.3,20 By presenting viral proteins in
novel ways, with or without specific adju-
vants, or by presenting both immunodo-
minant and subdominant epitopes,
specific beneficial memory responses may
be induced or augmented,13 and T-cell
anergy reversed. That said, even adminis-
tered in the context of cART, therapeutic
immunization is likely to have little effi-
cacy if used without other concomitant
immunotherapies due to the immuno-
compromised status of chronically HIV-
1-infected patients.20 In a study we
recently conducted, we hypothesized that
HIV-1-specific responses would be
enhanced by the administration of cyto-
kines and recombinant human growth
hormone (rhGH) in chronic treated HIV-
1 infection.17 Timing and delivery route
of immunization were carefully considered
in order to achieve the most robust
antigen-specific responses. In this Phase I
clinical trial, the FIT Biotech GTU
Multi-HIVB DNA vaccine was adminis-
tered via 10 intradermal injections result-
ing in modest immunogenicity, whereas
another therapeutic DNA vaccine study
reported markedly enhanced HIV-1-spe-
cific CD8 T-cell responses following
exfoliation of the skin and topical admin-
istration of the immunogen with a
patch.21 In vivo electroporation delivery
of a DNA vaccine was found to signifi-
cantly improve cellular immune responses
in terms of rate, magnitude, duration and
breadth to a number of antigens,22 which
concurred with results from animal mod-
els demonstrating improved responses
with electroporation.23 The GTU
Multi-HIVB vaccine used in untreated
Figure 1. Immunotherapy trial treatment schedule overview: A multifaceted approach. In our recent
study,17 patients were eligible to participate if they were over 18 y of age, chronically infected with
HIV-1, on a stable cART regimen for 6 months, with CD4 T-cell counts >400 cells/mm3 blood, and
plasma HIV-1 RNA<50 copies/ml. Subjects could not be receiving or have received immunomodula-
tory drugs or immunisation. Patients who met the eligibility criteria were randomized into one of 3
arms of the trial: Arm 1) to receive the GTU-MultiHIV DNA Clade B vaccine (FIT Biotech Plc, Tam-
pere, Finland) at baseline, followed by administration of IL-2 (Aldesleukin, Proleukin; Novartis, Cam-
berley, UK) and GM-CSF (Sargramostim, LeukineTM; Berlex, Seattle, WA) for 5 d during week 1, and
rhGH (Somatropin, SaizenTM; Merck-Serono International, Geneva, Switzerland) for 5 d during week
2, with vaccine further administered at weeks 6 and 12; Arm 2) to receive vaccine alone; or Arm 3)
to receive cytokines and rhGH alone, all at the aforementioned time points. Vaccine was adminis-
tered at 1mg/ml as 10 intradermal injections (5 100ml injections per arm); IL-2 given twice daily, 5 £
106 Units, administered by subcutaneous injection, 8h apart; GM-CSF, 150mg, was administered sub-
cutaneously once daily, 4h from the IL-2; and rhGH self-administered subcutaneously daily at 4mg/
day. Blood was drawn at 2 screen visits, at baseline (week 0) and at weeks 1, 2, 4, 6, 8, 12, 24 and 48.
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HIV-1C individuals induced antigen-spe-
cific responses, with beneficial effects on
plasma HIV-1 RNA and CD4 T-cell
recovery, particularly following intramus-
cular administration.20,24 Given the
renewed interest in therapeutic vaccines as
a component of latency reversal strategies,
it is of utmost importance to determine
the optimal timing and route of adminis-
tration, in addition to the choice of
immunogen.
Immunomodulatory Biologic
Agents and Timing of their
Administration
While previous immunotherapy stud-
ies have had limited efficacy to date, the
lessons we have learned from them
regarding the agents utilized and timing
of their administration must be used to
inform the rational design of future clini-
cal trials.3,9 Immunotherapy with cyto-
kines in conjunction with cART has been
explored as a way of purging the viral res-
ervoir, and targeting immune dysfunc-
tion.25 We have recently shown that
administration of IL-2 following immu-
nization as part of an immunotherapeutic
program that included granulocyte-mac-
rophage colony-stimulating factor (GM-
CSF) and rhGH was safe and well-toler-
ated. In this recent study, immunization
was used to prime specific cellular
responses within cART-treated-HIV-1C
individuals followed by the administra-
tion of a regime of cytokines/rhGH along
with further vaccine boosts designed to
augment and sustain memory T-cell
responses to HIV-1.3 Although the long-
term clinical benefit of IL-2 administra-
tion in HIV-1C subjects has been chal-
lenged, IL-2 therapy has been shown to
increase CD4 T-cell counts,26 reduce the
pool of resting CD4 T cells harbouring
replication-competent virus,27 and induce
HIV-1-specific T-cell responses.28 In our
trials utilizing IL-2 immunotherapy (bi-
daily subcutaneous administration of 5 £
106 Units), we demonstrated greater clin-
ical and immunological improvements
associated with this cytokine.15,17 The
potential of this cytokine to augment
virus-specific T-cell responses along
with therapeutic immunization and
antiretroviral drugs warrants further
investigation. In our studies, we have
shown IL-2 to be safe to administer with
side effects limited by pre-administration
prophylaxis.15,17,28 This lack of toxicity
was also reported for daily low-dose IL-2
therapy in HIV-1 infection.29 Timing of
IL-2 administration must be considered
with regard to any planned immunization
schedule. In animal models, relevant
responses were preserved and maintained
when IL-2 was administered during the
antigen-specific T-cell contraction phase
of the immune response.30,31 In contrast,
IL-2 given pre-immunization in HIV-1C
cART-treated patients failed to increase
specific T-cell proliferation.32,33 In 2 case
studies, IL-2 administered following teta-
nus immunization in HIV-1-infected per-
sons was found to better sustain tetanus-
specific T-cell responses than IL-2 given
together with vaccine or before immuni-
zation.34 Therefore IL-2 is likely to be
more beneficial for augmenting vaccine-
induced responses when given following
immunization. In the context of HIV-1
infection, GM-CSF has been reported to
increase CD4 T-cell counts and reduce
plasma HIV-1 RNA.35 GM-CSF acti-
vates
antigen-presenting cells, stimulates mac-
rophage differentiation and prolifera-
tion,36,37 and may target the viral
reservoir in these cells. In addition, IL-2
and GM-CSF have shown efficacy as
adjuvants for DNA- or peptide-based
vaccines.38 The use of rhGH to treat
HIV-1-associated wasting revealed
demonstrable improvements in a number
of factors, including quality of life.39
Immunological benefits of rhGH include:
reversal of thymic involution;40-43
increase in total and naive CD4 T-cell
counts;40,41,43,44 restoration of T-cell
responses against HIV-1;44-46 and reduc-
tion in expression of activation and apo-
ptosis markers.41 Pharmacological and
low doses of rhGH have been found to
be effective and confer clinical benefit
when administered for 12 weeks or
more,40–46 which should be taken into
account for future strategies.
The novel combination immunother-
apy approach was well-tolerated, and sub-
jects who received immunization, IL-2,
GM-CSF and rhGH showed the most
marked changes at the final study time
point compared to baseline.17 This com-
bination of cytokines, subsequent hor-
mone administration and immunization
resulted in a significant increase in CD4
T-cell counts, improved CD4/CD8 ratios,
enhanced functional T-cell responses to
Gag and a reversal of unfavorable (acti-
vated/exhausted) immunophenotypes. In
a previous study in which IL-2 was admin-
istered during weeks 0, 4 and 8, HIV-1-
specific lymphoproliferative responses
were not detected until week 24.28 These
responses were principally directed against
Gag p24, and associated with transient
’blips’ in plasma HIV-1 RNA levels.28
Such ’blips’ may provide a form of auto-
immunization, which could facilitate
greater immune control of the induced
latent reservoir. Similarly we reported a
delayed Gag-specific response at week
48,17 although the last dose of vaccine was
given at week 12, and these responses
were not associated with transient viral
’blips’. Transient ’blips’ in viraemia dur-
ing immunotherapeutic intervention or
latency reversal approaches may not neces-
sarily lead to de novo infection, since this
is thought to be prevented by cART.47
However, the pharmacokinetic profiles of
the drugs administered appear to be insuf-
ficient to enable complete tissue penetra-
tion, such that a program of cART
intensification should be considered in
this setting, for example including CCR5
antagonists.18,48 Administration of IL-2
and GM-CSF in cART-treated patients
with inadequate immune reconstitution
despite virological suppression was found
to result in HIV-1-specific proliferative
responses and IL-2 production.49 Changes
observed in our recent trial were most
striking for subjects who received all inter-
ventions, suggesting a combinatorial out-
come of these agents with distinct
biological effects. While there was an ini-
tial cytokine-induced immune activation,
which was short-lived, overall there was a
reduction in activation state for individu-
als who received IL-2 and GM-CSF com-
pared to subjects who did not receive
these cytokines. This was accompanied by
decreased surface expression of the nega-
tive regulator, programmed cell death 1
(PD-1), on both CD4 and CD8 T cells at
week 48 compared to baseline for all
www.tandfonline.com 2289Human Vaccines & Immunotherapeutics
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treatment groups regardless of randomiza-
tion, likely due to prolonged cART. The
percentage of HIV-1-specific CD4CIFN-
gCPD-1C T cells is significantly lower in
cART-treated patients compared to
untreated viraemic subjects,50 and PD-1
has been proposed as a marker to identify
incomplete immune reconstitution.51 In
the lymphocytic choriomeningitis virus
(LCMV) mouse model, blockade of IL-10
during therapeutic DNA immunization or
blockade of PD-1 during vaccinia vector
vaccination enhanced control of LCMV,
suggesting concurrent blockade of both
may be sufficient to restore exhausted cel-
lular immune responses.52,53 Combining
IL-2 administration and PD-1 ligand 1
(PD-L1) blockade in the mouse model of
LCMV reduced viral load and increased
virus-specific CD8 T-cell responses.54
These studies support the rationale for a
multifarious approach aimed at reversal of
HIV-1 latency and subsequent cure.
Proviral DNA and Quantiﬁcation
of Replication-Competent Virus:
Prospective Biomarkers to
Measure Reversal of Latency
Across a number of our studies we have
shown reductions in proviral HIV-1
DNA, be it with early cART, rhGH ther-
apy or combined vaccine/cytokine/hor-
mone immunotherapy.2,17,45 In our
recent study, on an individual patient
basis, subjects who showed the most
improved HIV-1-specific responses at
week 48 also showed a reduction of provi-
ral DNA, which might be due to the low
levels of proviral DNA at baseline, as these
individuals started cART in the first
month following diagnosis. To date there
is no universally agreed method to accu-
rately quantify latent infection, i.e. mea-
surement of the proportion of integrated
HIV-1 DNA capable of infectious virion
production.
Long-lived resting memory CD4 T
cells along with other tissue reservoirs
that include the brain, lymphoid tissue
(lymph node and gut), bone marrow,
and genital tract, may each contribute
to viral rebound and are difficult to
sample clinically. In some of these tissue
reservoirs drug concentrations may be
suboptimal.55 Understanding the gener-
ation and maintenance of latent provi-
ruses and latently infected T cells is
central to HIV-1 cure strategies, how-
ever the mechanisms involved are com-
plex56 and beyond the scope of this
commentary. Currently, at least 2 steps
are thought to be essential: HIV-1
induction and expression from latently
infected cells; and virus-specific CTL
recognition and killing of infected cells.
Studies evaluating the extent of latency
and potential for its reversal have been
varied.57 The vast majority of viruses in
the latent reservoir of patients treated
during chronic HIV-1 infection com-
prise CTL escape mutations, which are
rare in the reservoirs of subjects treated
during acute infection.13 Recent work
shows that only 12% of proviruses are
non-mutated and replication compe-
tent.58 However, measurement of HIV-
1 latency reversal ex vivo using a differ-
ent approach revealed that only 1.5% of
proviruses in resting CD4 T cells were
able to produce virions following CD3/
CD28 activation. Considering the high
proportion of defective provirus in the
latent reservoir (88–98.5%), an agreed
method to accurately measure potential
latency reversal by various candidate
agents is urgently needed.59,60 The
reported failures of various first genera-
tion latency reversal agents on their
own resulted in modifying such
approaches. To date, a number of
potential latency reversal agents have
failed to upregulate HIV-1 gene expres-
sion in resting CD4C T cells from
treated patients, with the exception of
the protein kinase C agonist, bryostatin-
1.47,59 The next generation of candidate
agents will hopefully yield more promis-
ing results. Ongoing and planned trials
of these interventions are incorporating
the strategies we have reviewed here,
including early cART, therapeutic
immunization, cytokines and cART
intensification (Table 1). A number of
clinical trials are optimizing dosing,
sequence and timing, in addition to uti-
lizing multifaceted approaches. Combi-
nations of drugs with pharmacokinetic
profiles that achieve comprehensive tis-
sue distribution are needed to target
latency, as we fill gaps in our knowledge
regarding in vivo latency mechanisms.
As mentioned, the methods to measure
latency reversal are varied. This is par-
ticularly troubling because the emerging
consensus is that existing assays either
overestimate or underestimate the size
of the latent HIV-1 reservoir.47 The
ultimate measure of success for latency
reversal strategies will be structured
treatment cessation, though this
approach must be used with great
caution.5,6
Conclusions and Perspectives
Irrespective of the mechanisms
responsible for the establishment of
HIV-1 latency, it represents a major
hurdle for HIV-1 clearance. A number
of agents and strategies have been pro-
posed to activate latent HIV-1 in order
to deplete the reservoir by a combina-
tion of viral cytopathic effects and
modulated cell-mediated immunity ulti-
mately resulting in control of HIV-1
replication. Such control is observed in
long-term nonprogressors or HIV con-
trollers and forms the foundation for
functional cure. Larger studies employ-
ing various biological agents and accu-
rate quantification of latency reversal are
needed to fully elucidate the clinical
benefit of these therapies. Approaches
aimed at purging virus by stimulating
HIV-1-specific T cells in the absence of
potentially detrimental global T-cell
activation, need not abandon strategies
employing low-dose IL-2 immunother-
apy in addition to treatment with other
agents described herein. Whether at
lower physiological or higher pharmaco-
logical doses, current candidate agents
have been associated with improved thy-
mic function, enhanced T-cell function-
ality, lessened immune activation, and
reduced proviral DNA; again lending
weight to the idea of synergistic
approach. Longer-term follow-up would
assess whether or not these improve-
ments are maintained. Current endeav-
ors seek to establish consensus on
combined therapies, their optimal tim-
ing and dosing, given the antigen loss
post-cART. There has been an optimis-
tic shift toward the development of
2290 Volume 11 Issue 9Human Vaccines & Immunotherapeutics
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curative strategies, in which the focus of
prospective immunotherapy will not
only be to induce and maintain
increased T-cell functionality, improve
immunophenotypes and confer clinical
benefit, but also to target the latent res-
ervoir. While eradication of the reservoir
is the aim of a sterilizing cure, contain-
ment of the reservoir is essential to
achieve a functional cure of HIV-1
infection. Successful immunological
approaches may require different step-
wise novel interventions, grouping of
existing and new generation immuno-
therapeutic and latency reversal agents,
and larger patient cohorts, alongside the
development of accurate and consensus
measurement of latency reversal, to
result in curative intervention. Further
detailed investigations are required to
identify immunological, virological and
clinical biomarkers for accurate assess-
ment of end-point efficacy in the
approaches described.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were
disclosed.
Table 1. Immunotherapeutic interventions and their potential for HIV-1 latency reversal: A combined approach to induce cure of HIV-1 infection
Intervention Immunological beneﬁts HIV-1 reservoir and latency reversal
None Infected CD4C lymphocytes and cells of the monocytic lineage;
dysfunctional APC; dysregulated NK cells; excessive immune
activation; immunosuppression; T-cell anergy and
unresponsiveness to HIV-1
Establishment of the latent reservoir
cART during chronic HIV-1 infection Increased numbers of CD4 T cells (including na€ıve); functional
improvement in T-cell responses to recall antigens; partial
normalization of activation, exhaustion, and regulatory
function; some normalization of NK cell and APC function;
incomplete reconstitution of fully functional HIV-1-speciﬁc
CD4 and CD8 T-cell responses
Persistence of latent reservoir not impacted
by either cART or immune
reconstitution; latent reservoir
dominated by CTL escape mutations
cART during acute HIV-1 infection Increased numbers of CD4 T cells (including na€ıve); improved
polyfunctionality of HIV-1-speciﬁc responses; enhanced
immune reconstitution and better response to immunisation/
immunotherapy
Reduced size of the latent viral reservoir
comparable to that observed in LTNP;
latent viruses carry fewer CTL escape
mutations
cART intensiﬁcation (e.g. CCR5
antagonists)
Favourably adjusts HIV-1 associated T-cell activation and
differentiation proﬁles; prevention of de novo infection of
susceptible cells from viral replication or reactivation
Potential to prevent reservoir re-seeding
HIV-1 immunogens Provision of unpathogenic antigenic stimulation; induced/
boosted anti-HIV-1 functional responses (new and memory)
Potential to deplete viral reservoirs (or at
least reduce these to levels observed in
LTNP or elite controllers)
Cytokines (e.g., IL-2) Increased numbers of CD4 T cells; improved T-cell growth,
survival, differentiation/maturation; reversal of T-cell anergy;
regulation and maintenance of T cells along distinct
differentiation pathways; increased frequency and function of
T effectors and Tregs, particularly HIV-1-speciﬁc CD4 HTL and
CD8 CTL
Lower numbers of HIV-1-infected latent
CD4 T cells; potential to purge virus
through transient viral ‘blips’
Cytokines (e.g. GM-CSF) Reversal of anergy; increased T effector cells; increased frequency
of HIV-1-speciﬁc HTL and CTL; enhanced APC and NK cell
function
Potential to purge viral reservoirs in cells of
the monocytic lineage
Hormones (e.g., rhGH) Increased thymic activity; increased pool of na€ıve T cells;
decreased systemic hyperactivation; restored differentiation/
maturation, prevention of apoptosis, and promotion of
proliferation; increased NK cell function
Possible impact on integrated provirus
Latency reversal agents (e.g. protein
kinase C agonists)
HIV-1 induction and expression from latently infected cells;
proteins/peptides processed and presented to immune cells
Potential to reactivate the latent viral
reservoir in infected resting CD4C cells;
however stimulation of HIV-1-speciﬁc
CTL prior to reactivating latent HIV-1 is
thought to be crucial; successful
strategies might include HIV-1
immunogens and low-dose IL-2
Immune modulatory drugs (e.g., PD-
1/PD-L1 blockade)
Restoration of proliferative and effector function of CD4 and CD8
T cells, respectively; restoration of HIV-1-speciﬁc CD8 T-cell
effector function due to reversal of exhaustion
Impact on HIV-1 reservoir to be determined
APC, antigen-presenting cell; cART, combination antiretroviral therapy; CTL, cytotoxic T lymphocyte; GM-CSF, granulocyte macrophage colony stimulating
factor; HDAC, histone deacetylase; HTL, helper T lymphocyte; IL-2, interleukin-2; LTNP, long-term nonprogressor; NK, natural killer cell; PD-1, programmed
cell death-1; PD-L1, PD-1 ligand 1; rhGH, recombinant human growth hormone; T-reg, regulatory T cell.
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